Blog Posts

Recent Supreme Court Ruling Could Affect 340B Dispute Resolution Lawsuits

A recent U.S. Supreme Court decision involving medical device manufacturer Arthrex could influence lawsuits over the 340B program’s administrative dispute resolution (ADR) process.

A U.S. Supreme Court decision in late June about the appointment of federal administrative patent judges (APJs) could influence the outcome of several ongoing lawsuits over the 340B program’s administrative dispute resolution (ADR) process.

 

Please

Read More »

Breaking: Merck Will End 340B Contract Pharmacy Pricing for Hospitals That Don’t Share their Claims Data

Drug manufacturer Merck has begun informing 340B covered entities that, effective Sept. 1, it will stop providing 340B pricing to hospitals on its drugs shipped to contract pharmacies, if the hospitals do not provide their 340B claims data.

Drug manufacturer Merck has begun informing 340B covered entities that, effective Sept. 1, it will stop providing 340B pricing to hospitals that partner with 340B contract pharmacies unless the hospitals share 340B claims data with its vendor 340B ESP.

Read More »

In Strongly Worded Brief in United Therapeutics Case, Feds Defend 340B Contract Pharmacy Actions

Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge yesterday.

Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge in

Read More »

Feds and AstraZeneca Trade Punches in Drug Maker’s 340B Lawsuit

Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.

Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.

Please Login or

Read More »

Biden Lays Down Markers for Action to Lower Drug Prices

President Biden this morning called on Congress to let Medicare negotiate drug prices and make drug companies that raise their prices faster than inflation pay a penalty.

President Biden this morning called on Congress to let Medicare negotiate drug prices and penalize drug companies that raise their prices faster than inflation.

 

Please Login or Become a Paid Subscriber to View this Content

Read More »

U.S. Senate Sets Stage for Action on Lowering Drug Prices

U.S. Senate Democrats, led by Chuck Schumer (N.Y.), are setting the stage for a vote soon on policy changes to lower drug prices.

The U.S. Senate on Tuesday voted 69-30 to pass a bipartisan infrastructure bill that includes two drug pricing provisions, neither directly 340B-related. The bill now moves to the U.S. House, which is on a seven-week summer break. The $1 trillion

Read More »

PhRMA Urges Court Again to Strike Down 340B Dispute Resolution Process

PhRMA's lawsuit challenging the 340B administrative dispute resolution process is being heard in federal district court in Baltimore.

Regulations establishing a binding administrative dispute resolution (ADR) process for the 340B program were rushed into place last December to defeat lawsuits, are fatally flawed legally and constitutionally, and should be struck down, the main U.S. trade association for drug

Read More »

Biden Wants to Rescind Trump’s Most Favored Nation Proposal That Received Widespread Criticism from Drug Industry and 340B Providers

The Biden administration plans to rescind ex-President Trump's Most Favored Nation interim final rule that would peg Medicare reimbursement for some drugs to the lowest price that drug manufacturers get in similar countries.

The Biden administration plans to rescind a published but unimplemented Trump-era regulation that would peg Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers get in similar countries.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content